In vitro evaluation of potential transporter ‐mediated drug interactions of evogliptin

The objective of this study was to evaluate the DDI potential of evogliptin using various in vitro assays in transporter‐expressing cell lines. After incubating evogliptin with cells overexpressing OAT1, OAT3, OCT2, OATP1B1, and OATP1B3, there was no notable cellular accumulation of evogliptin (fold accumulation, 0.41–1.86). In bidirectional transport assays using Caco‐2 cell monolayer, a high efflux ratio (ER, 522) of evogliptin was observed, which was significantly decreased (97.96%) in the presence of a potent P‐gp inhibitor. In assays using MDCKII‐BCRP cell monolayers, by contrast, a low net ER (1.16‐1.26) was found. In similar cellular uptake and bidirectional studies with probe substrates of P‐gp, BCRP, OAT1, OAT3, OCT2, OATP1B1, and OATP1B3, active transport of the substrates was not significantly suppressed by evogliptin. These results suggest that evogliptin may be a substrate of P‐gp, but not a substrate of BCRP, OAT1B1, OAT1B3, OAT1, OAT3, or OCT2, and not an inhibitor of any of these transporters. Therefore, it could be concluded that evogliptin has some DDI potential involving P‐gp, but it has low potential of DDI mediated by the other transporters.
Source: Biopharmaceutics and Drug Disposition - Category: Drugs & Pharmacology Authors: Tags: SHORT COMMUNICATION Source Type: research